Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles

Published:2014-10 Issue: Volume:192 Page:114-121
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Liu Yang,Zhu Yan-Hua,Mao Cheng-Qiong,Dou Shuang,Shen Song,Tan Zi-Bin,Wang Jun

Funder

National Basic Research Program of China

National High Technology Research and Development Program of China

National Natural Science Foundation of China

SRFDP

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference59 articles.

1. Global cancer statistics;Jemal;CA Cancer J. Clin.,2011

2. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research;Bosch;Cancer Treat. Rev.,2010

3. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients;Tan;Breast Cancer Res. Treat.,2008

4. Triple negative tumours: a critical review;Reis-Filho;Histopathology,2008

5. Early breast cancer trialists collaborative, Tamoxifen for early breast cancer: an overview of the randomised trials;Clarke;Lancet,1998

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On discovery of novel hub genes for ER+ and TN breast cancer types through RNA seq data analyses and classification models;Scientific Reports;2024-09-06

2. Precision arrows: Navigating breast cancer with nanotechnology siRNA;International Journal of Pharmaceutics;2024-09

3. Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy;Bioengineering;2024-08-14

4. Wild-type IDH2 is a therapeutic target for triple-negative breast cancer;Nature Communications;2024-04-24

5. Infiltrative Vessel Co-optive Growth Pattern Induced by IQGAP3 Overexpression Promotes Microvascular Invasion in Hepatocellular Carcinoma;Clinical Cancer Research;2024-03-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3